Latest news
Liquid TKI Formulations Could Address Long-Standing Dosing and Adherence Challenges in GIST Management - OncLiveOncLive · Sat, 08 Aug 2026 11:59:48 GMTMetastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition - OncodailyOncodaily · Fri, 07 Aug 2026 14:44:09 GMTDe-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study - springermedicine.comspringermedicine.com · Thu, 06 Aug 2026 07:00:00 GMTEYPT: DURAVYU advances as a potential first-in-class, long-acting TKI for major retinal diseases - TradingViewTradingView · Tue, 04 Aug 2026 11:21:19 GMTOCUL: AXPAXLI (OTX-TKI) shows up to 72% reduction in injection burden versus aflibercept - TradingViewTradingView · Sun, 02 Aug 2026 11:19:47 GMTThe Dose Is Too High: Rethinking TKI Dosing - MedscapeMedscape · Fri, 31 Jul 2026 13:24:53 GMTIvonescimab Improves Survival After EGFR-TKI Failure - OncodailyOncodaily · Thu, 30 Jul 2026 07:00:00 GMT